Biotech and Donald Trump: A conversation about what comes next

This story was adapted from Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Adam: Hey Matt, welcome to my newsletter! 

Matt: It’s surprisingly spacious inside here. 

advertisement

Adam: I try to make it as comfy as possible. The election. Wow, a lot to think about. Let’s start with the Food and Drug Administration, because there’s so much uncertainty over what might happen at, or to, the agency in Trump’s second term. I took some comfort in something you wrote in your piece yesterday. You said

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe